Cargando…
An improved Bacillus subtilis cell factory for producing scyllo-inositol, a promising therapeutic agent for Alzheimer’s disease
BACKGROUND: Bacillus subtilis 168 possesses an efficient pathway to metabolize some of the stereoisomers of inositol, including myo-inositol (MI) and scyllo-inositol (SI). Previously we reported a prototype of a B. subtilis cell factory with modified inositol metabolism that converts MI into SI in t...
Autores principales: | Tanaka, Kosei, Tajima, Shintaro, Takenaka, Shinji, Yoshida, Ken-ichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878828/ https://www.ncbi.nlm.nih.gov/pubmed/24325193 http://dx.doi.org/10.1186/1475-2859-12-124 |
Ejemplares similares
-
A new-generation of Bacillus subtilis cell factory for further elevated scyllo-inositol production
por: Tanaka, Kosei, et al.
Publicado: (2017) -
A cell factory of Bacillus subtilis engineered for the simple bioconversion of myo-inositol to scyllo-inositol, a potential therapeutic agent for Alzheimer's disease
por: Yamaoka, Masaru, et al.
Publicado: (2011) -
Bacillus subtilis IolQ (DegA) is a transcriptional repressor of iolX encoding NAD(+)-dependent scyllo-inositol dehydrogenase
por: Kang, Dong-Min, et al.
Publicado: (2017) -
A bacterial cell factory converting glucose into scyllo-inositol, a therapeutic agent for Alzheimer’s disease
por: Michon, Christophe, et al.
Publicado: (2020) -
Antiepileptic Properties of Scyllo-Inositol on Pentylenetetrazol-Induced Seizures
por: Wiśniewski, Karol, et al.
Publicado: (2023)